Jatinder Chopra
Pulmonary Disease · Tulare, CANPI 1659387652
Payments from drug & device makers
Across 321 payments — averaging $39.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- GSK$733
- Amgen$622
- AbbVie$401
- plus $3K from 29 others
What the payments were for
- Food & beverage$12,659100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $4,203 |
| Novo Nordisk | 104 | $2,594 |
| Lilly USA, LLC | 36 | $1,072 |
| GSK | 23 | $733 |
| Amgen | 15 | $622 |
| AbbVie(2 entities) | 7 | $401 |
| Mylan Specialty L.p. | 14 | $344 |
| Amarin Pharma, Inc. | 2 | $278 |
| Boehringer Ingelheim | 6 | $255 |
| Idorsia Pharmaceuticals US Inc | 7 | $214 |
| Alk-abello, Inc | 2 | $178 |
| Novartis | 3 | $148 |
| Abbott | 2 | $142 |
| Avanir Pharmaceuticals, Inc. | 1 | $141 |
| Braeburn Inc. | 1 | $128 |
| Corcept Therapeutics | 2 | $128 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $123 |
| Bio Products Laboratory USA, Inc. | 1 | $115 |
| Lexicon Pharmaceuticals, Inc. | 1 | $111 |
| Dynavax Technologies Corporation | 1 | $107 |
| Merck | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $75 |
| Exact Sciences | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Pfizer | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Coopersurgical, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,659 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $126,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $52,382 |
| FarxigaDapagliflozin Propanediol | 44 | $40,045 |
| JanuviaSitagliptin Phosphate | 37 | $38,104 |
| EliquisApixaban | 41 | $36,669 |
| JardianceEmpagliflozin | 30 | $33,047 |
| TrulicityDulaglutide | 20 | $25,298 |
| XareltoRivaroxaban | 25 | $23,353 |
| EntrestoSacubitril/Valsartan | 12 | $16,046 |
| MyrbetriqMirabegron | 21 | $13,578 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $12,088 |
| MounjaroTirzepatide | 11 | $11,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,428 |
| MotegrityPrucalopride Succinate | 13 | $6,943 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 212 | $6,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,594 | $126,939123 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $733 | $61,859101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $4,203 | $51,47363 claims |
| MerckJanuvia | $102 | $38,10437 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,072 | $36,84631 claims |
| PfizerEliquis | $33 | $36,66941 claims |
| Boehringer IngelheimJardiance | $255 | $33,04730 claims |
| Johnson & JohnsonXarelto | $21 | $23,35325 claims |
| NovartisEntresto | $148 | $16,04612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $75 | $6,94313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Tulare
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.